ArticleJHLT open2026
Outcomes of microaxial flow pump use in acute-on-chronic heart failure.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mortality rate associated with acute decompensated heart failure (ADHF) is high, and prognosis depends on restoring cardiac output. Patients frequently require mechanical circulatory support (MCS). The Impella microaxial flow pump (mAFP) is a short-term MCS used to stabilize patients. We report outcomes of mAFP use in patients with pre-existing chronic heart failure who presented with ADHF. Materials and Methods: This retrospective single-center study included all patients with a history of chronic heart failure who presented with ADHF and were managed with mAFP. Demographic characteristics, hemodynamic variables, complications, and clinical outcomes were evaluated. Results: Fifty-eight patients were included. Patients were managed with the Impella 5.5/5.0 ( Conclusion: The mAFP demonstrates favorable outcomes in patients with chronic heart failure who present with ADHF. It resulted in significant improvements in hemodynamic parameters, and most patients survived to durable LVAD or transplantation. In this heterogenous patient group, only a few survived definitive weaning from mAFP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.